Lipril (Lisinopril)

Lisinopril blocks the angiotensin‑converting enzyme, stopping the formation of angiotensin II, a powerful vasoconstrictor. With less angiotensin II, blood vessels relax, blood pressure falls, and the body releases less aldosterone, decreasing fluid retention and protecting the heart and kidneys.

The dose of Lipril is individualized by a qualified prescriber based on the patient’s medical condition, response to therapy, and renal function. The prescribing clinician determines the appropriate strength, frequency, and any necessary dose adjustments.

Lisinopril is generally contraindicated in pregnancy because it may harm the developing fetus, especially in the second and third trimesters. Limited data exist for breastfeeding; therefore, the drug should only be used if the potential benefit outweighs the risk, under medical supervision.

To request Lipril, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lipril (lisinopril) shares the same mechanism as other ACE inhibitors such as enalapril or ramipril, offering comparable blood‑pressure‑lowering effects. Differences may lie in dosing frequency, half‑life, and individual patient tolerance, so clinicians choose the agent that best fits the patient’s overall treatment plan.

Lipril should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lipril is taken orally, usually once daily, with or without food, as directed by the prescribing physician. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

The most serious adverse events include angioedema, which can affect the airway, severe hypotension especially after the first dose, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, faintness, or a sudden decline in urine output.

Lipril is contraindicated in individuals with a known hypersensitivity to lisinopril or any ACE inhibitor, a history of angioedema related to ACE‑inhibitor therapy, and in patients with hereditary or idiopathic angioedema of the upper airway. Caution is also advised for those with severe renal impairment.